Ajanta Pharma and Cadila Healthcare have reported that their manufacturing facilities have completed successful USFDA inspection without any adverse observation.

Cadila's Moraiya facility was audited by USFDA as a surprise inspection which was triggered due to the product recalls last year. Moraiya is key facility for Cadila as significant number ANDAs are filled from this facility. This facility had been under import alert prior to its clearance by the USFDA last year. – IIFL 


 

Digital version